washington los angeles  reuters    u s  president donald trump in a meeting on tuesday with pharmaceutical executives called on them to manufacture more of their drugs in the united states and cut prices  while vowing to speed approval of new medicines and ease regulation   trump told them the government was paying  astronomical  prices for medicines in its health programs for older  disabled and poor people and said he would soon appoint a new u s  food and drug administration leader   we re going to streamline the fda   trump said in a statement  referring to the regulatory agency responsible for vetting that new drugs are safe and effective  the meeting between trump and the pharmaceutical executives signaled a defusing of tensions that have kept drug stock prices in check since the presidential election  shares of most of the group rallied on tuesday following the meeting  even as the broader stock market slid   trump is a populist above all else  and having these  drug  prices skyrocket  he s commented that under his administration  this is not going to happen   said market strategist quincy crosby of prudential financial in newark  new jersey  she said trump was playing a balancing act between controlling prices and loosening regulations   i don t think the majority of americans want all regulations lifted from drug makers   attending the meeting were top executives at merck   co inc  johnson    celgene corp  eli lilly   co  amgen inc and switzerland s novartis ag  nov n s  as well as the head of the pharmaceutical research and manufacturers of america  phrma  lobbying group   according to a transcript of the televised portion of the meeting  amgen chief executive officer robert brad way promised to add   u s  jobs at his california based biotechnology company this year   amgen clarified in an email that it currently employs around   people worldwide  including   in the united states  and said the   includes new staff as well as hires to address attrition   celgene  lilly  merck and amgen said by email after the meeting that they were encouraged by trump s focus on innovation  tax reform and the need for a more value driven health care system  lilly said discussion topics also included stronger trade agreements and removing  outdated regulations that drive up costs and slow innovation   phrma echoed those points in its own post meeting statement  adding that the policies  if enacted  would result in up to   new jobs over the next  years   tax  deregulation   those are things that could really help us expand operations   lilly ceo dave ricks said  officials at novartis and j j did not immediately respond to requests for additional comment   shares of the six companies were mostly higher  for an overall gain averaging   percent  compared with a   percent drop in the broad s p   the nasdaq biotech index was up   percent  reversing earlier losses  and the s p  health care index gained   percent        we have to get prices down for a lot of reasons  we have no choice  for medicare and medicaid   trump said  citing the nation s government insurance programs for the elderly  the poor and the disabled  trump also said currency devaluation by other countries had increased drugmakers  outsourcing their production  and he called on the companies to make more of their products in the united states   foreign countries must pay a fair share for drug development costs  he added   we re going to end global freeloading     the united states typically pays more for drugs than any other developed nation  most western european countries  as well as japan  have government run health care coverage under which drug prices are negotiated   high drug prices have become a national issue during the past two years as healthcare costs have risen trump spooked pharmaceutical and biotech investors by saying on jan    before his inauguration  that drug companies were  getting away with murder  on what they charged the government for medicine and that he would do something about it   company executives  meanwhile  have tried to tread a careful line in defending their industry while expressing optimism that the united states would continue to reward scientific advances    regulations   great  streamlining the fda  perhaps   jack ablin  chief investment officer at bmo private bank in chicago said   but if trump is going to address his constituency  drug prices have to come down  so i think this is maybe a pyrrhic victory   